Table 1.

Summary of Clinical Studies Investigating the Clinical Usefulness of Fructosamine and Glycated Albumin in Diabetes.

Authors	Endpoint	n	Outcome	Reference
Shima et al 1989	Screening of impaired glucose tolerance	302	GA: Significantly higher values in subjects with impaired glucose tolerance FA: Values nonsignificantly different between controls and subjects with impaired glucose tolerance	35
Furusyo et al 2011	Screening of diabetes	1575	GA: AUC of 0.91 for screening diabetes	36
Li et al 2011	Screening of diabetes	1480	GA: AUC of 0.88 for screening diabetes	37
Selvin et al 2011	Prediction of diabetic complications	1600	GA: OR of 3.8-9.3 for diabetic complications FA: OR of 5.9-6.3 for diabetic complications	38
Yang et al 2012	Screening of diabetes	1211	GA: AUC of 0.86 for screening diabetes	39
Malmström et al 2014	Screening of diabetes	10987	FA: AUC of 0.95 for screening diabetes	40

AUC, area under the curve; FA, fructosamine; GA, glycated albumin; OR, odds ratio.